Article Information
History
- February 15, 2021.
Article Versions
- You are currently viewing Version 1 of this article (February 15, 2021 - 12:51).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Fang Tian1,#,
- Bei Tong2,#,*,
- Liang Sun3,
- Shengchao Shi1,
- Bin Zheng1,
- Zibin Wang3,
- Xianchi Dong3,4,* and
- Peng Zheng1,4,*
- 1State Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, Jiangsu, 210023, China
- 2Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing, 210014, China
- 3State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, China
- 4Engineering Research Center of Protein and Peptide Medicine, Ministry of Education, China
- ↵*Corresponding authors: pengz{at}nju.edu.cn, beitong{at}cnbg.net, and xianchidong{at}nju.edu.cn
↵# These authors contributed equally to this work
Posted February 15, 2021.
Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2
